October 9-11, 2019
Hyatt Regency San Diego, CA, USA 

IKSUDA Therapeutics

Partner

Iksuda Therapeutics (formally Glythera) is a pre-clinical stage company developing ADCs for difficult to treat solid tumours. Our ADCs are centered around our proprietary PermaLInk® conjugation platform which provides conjugation stability by design.

Through PermaLink, we aim to develop more effective ADCs by leveraging the broad tumour activity associated with ultra-potent DNA damaging payloads, combined with clinically relevant targets.

Through our collaborations and partnerships, we are building a pipeline of superior ADCs with the goal of improving the lives of patients living with cancer.

www.iksuda.com